Form 4: Day One Biopharmaceuticals Acquired by Servier

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals for $21.50 per share in an all-cash transaction.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) completed its merger with Servier Pharmaceuticals LLC on April 23, 2026.
• All outstanding shares of common stock were converted into the right to receive $21.50 per share in cash.
• All outstanding unvested stock options and restricted stock units (RSUs) became fully vested immediately prior to the merger.
• Equity awards were canceled and converted into cash payments based on the merger consideration, minus applicable exercise prices and taxes.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the filing confirms the successful completion of a definitive merger agreement at a fixed cash price.

Positives

• Shareholders received a definitive cash exit at $21.50 per share.
• All unvested equity awards held by the reporting person were accelerated and vested in full upon the merger closing.

Negatives

• The company has ceased to be an independent publicly traded entity following the acquisition.

Risks

• No ongoing operational risks as the company is now a wholly owned subsidiary of Servier Pharmaceuticals.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; no further independent public guidance is provided.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies acquiring specialized biotech firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The acquisition follows standard industry practices for biotech M&A, involving full acceleration of equity awards for management and employees upon change of control.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management with equity awards received accelerated vesting and cash payouts.

Next Steps

• Delisting of Day One Biopharmaceuticals (DAWN) from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Servier Pharmaceuticals, Merger, Acquisition, SEC Form 4, Biotech